Serial MRI Scans During Radiation Therapy (RELAY)
Glioblastoma, Esophageal Cancer, Radiotherapy
About this trial
This is an interventional other trial for Glioblastoma focused on measuring Glioblastoma, Esophageal Cancer, Radiotherapy, Magnetic Resonance Imaging, MRI, Prostate Cancer, Vulvar Cancer, Pediatric Glioblastoma Multiforme
Eligibility Criteria
Inclusion Criteria:
- Participants must have a confirmed malignancy requiring radiation therapy.
- Age: 18 years or older
- ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A)
- Ability to understand and the willingness to sign a written informed consent document.
Any further criteria listed in the specific disease site sub protocol
- Patients must be considered appropriate candidates for neoadjuvant chemoradiation therapy followed by esophagectomy
- Patients with a histologically confirmed newly diagnosed intracranial glioblastoma or gliosarcoma who will be undergoing radiation therapy as part of clinical care.
- Patients with localized prostate caner who are planned to receive androgen deprivation therapy and definitive radiation therapy.
- Patients with Biopsy-proven locally advanced vulvar cancer for which definitive radiotherapy is planned
- Patients who are age 18 or under (or 18-30 if physician determines that biology is consistent with pediatric high grade glioma) with a histologically confirmed newly diagnosed high-grade glioma (WHO grade III or IV) who will be undergoing radiation therapy as part of clinical care. Patients with DIPG are only eligible if biopsy-confirmed high grade DIPG is present.
Exclusion Criteria
- Disease-specific exclusion criteria will be specified in a sub protocol.
For MRI involving contrast, history of allergic reactions attributed to gadolinium based IV contrast.
-- Note: If patient will not receive contrast, this is not applicable and kidney function will not affect eligibility
- Unable to undergo magnetic resonance imaging (MRI)
Sites / Locations
- Brigham and Women HospitalRecruiting
- Dana Farber Cancer InstituteRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Arm 6
Arm 7
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Experimental
Esophageal Cohort
Glioblastoma Cohort
Glioblastoma Expansion Cohort Serial MR Imaging Registry
Prostate Cancer Cohort
Prostate Cancer Expansion Cohort Serial MR Imaging Registry
Vulvar Cancer Cohort
Pediatric Glioma Cohort
The research study procedures include: Screening for eligibility Three MRI scans (prior to start of standard cancer treatment, in the middle, and at the end of radiation treatment). Imaging with MRI will be performed as per disease site standards.
The research study procedures include: Screening for eligibility Three MRI scans prior to start of standard cancer treatment, in the middle, and at the end of radiation treatment). Imaging with MRI will be performed as per disease site standards.
The research study procedures include: Screening for eligibility Three MRI scans prior to start of standard cancer treatment, in the middle, and at the end of radiation treatment). Imaging with MRI will be performed as per disease site standards.
The research study procedures include: Screening for eligibility Three MRI scans prior to start of androgen deprivation therapy, prior to the start of radiation treatment, and after radiation treatment). Imaging with MRI will be performed as per disease site standards. Genomic testing of biopsy sample
The research study procedures include: Screening for eligibility Three MRI scans prior to start of androgen deprivation therapy, prior to the start of radiation treatment, and after radiation treatment). Imaging with MRI will be performed as per disease site standards. Genomic testing of biopsy sample
The research study procedures include: Screening for eligibility Three MRI scans prior to start of standard cancer treatment, in the middle, and at the end of radiation treatment). Imaging with MRI will be performed as per disease site standards.
The research study procedures include: Screening for eligibility Three MRI scans prior to start of standard cancer treatment, in the middle, and at the end of radiation treatment). Imaging with MRI will be performed as per disease site standards.